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“We are all naturally dependent on opioids for our emotional health.”  
 
                                                                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INRODUCTION 
 
The milky fluid extracted from the Papaver somniferum plant's seed-capsule 
(‘poppyhead’) is highly narcotic after drying.  This product is referred as 
opium. The word ‘opium’ derives from the Greek word for juice of a plant. 
Opioids have been the mainstay of pain treatment for thousands of years, and 
they remain so today. Opioid receptors are cell surface glycoproteins and they 
are tightly integrated into the cell membranes.  Opioids are the most effective 
analgesic drugs for acute and chronic pain. Opioid system consists of mu- 
(MOP) delta- (DOP) kappa (KOP) nociceptin (NOP) opioid receptors and 
endogenous opioid peptides (enkephalins, -endorphin, dynorphins and 
nociceptin or N/OFQ) (Corbett et al 2006). All the endogenous opioid 
peptides are derived from four precursor polypeptides named as 
proenkephalin (PENK), prodynorphin (PDYN), proopiomelanocortin (POMC) 
and pronociceptin (PNOC).  While PENK is source for the two enkephalin 
pentapeptides (Met- and Leu-enkephalin, YGGFM and YGGFL respectively), 
PDYN is source for dynorphins.  Beside the enkephalins, PENK is also 
precursor for the Met-enkephalin extended heptapeptide, Met-enkephalin-
Arg6-Phe7 (YGGFMRF) and octapeptide, Met-enkephalin-arg6-gly7-leu8 
(YGGFMRGL) sequences (Patey and Rossier, 1986).  
Artificial hexapeptides isolated from peptide combinatorial chemical libraries 
are amongst the most selective ligands for the NOP receptor.  One leading 
compound in this series is Ac-RYYRIK-NH2, developed by Dooley (Dooley 
et al 1996). Recently a close derivative with a reduced C-terminus, 
Ac-RYYRIK-ol has been described by our group as a partial agonist at the 
NOP receptors using various in vitro and in vivo studies (Gündüz et al., 2006).  
Being a partial agonist with intrinsic antagonist potency, this hexapeptide 
alcohol is capable of inhibiting competitively some effects mediated by full 
agonists at the NOP receptor. A further analogue, Ac-RYYRIR-ol, 
representing the Lys6Arg6 replacement of its parent compound Ac-
RYYRIK-ol, has been synthesized aiming even better potency.   
 
AIM OF THE STUDIES 
 
Main objective of the present studies were; 
 
 To collect all available PENK and PDYN sequences from the public 
database (PubMed, Ensmbl etc.) and align them to characterize phylogenetic 
variability of the opiod peptides within the precursors, 
 
 To chemically synthesize and to characterize the novel opioid sequences 
using comparative biochemical methods such as receptor binding and 
G-protein activation assays,  
 
 To investigate the pharmacological properties of Ac-RYYRIR-ol using 
various in vitro assays, such as receptor binding, G-protein activation, mouse 
vas deferens, guinea pig ileum, and mouse colon bioassays, and calcium ion 
mobilization experiments. 
 
 To study the effective radiolabeling and detailed receptor binding 
properties of the newly developed radioligand [3H]Ac-RYYRIK-ol to native 
and recombinant NOP receptors. 
 
METHODS 
 
Inbred Wistar rats, guinea pigs (R9strain) and CHO cells stably expressing the 
wild type human nociceptin (hNOP) receptor protein (Dr Jean-Claude 
Meunier, Toulouse, France) were used for the studies. Recombinant HEK293 
cells expressing the fusion construct hNOP-GFP (Dr. Maithe Corbani 
Montpellier, France) were used for the receptor internalization experiments. 
All the peptides were prepared by Dr. Magyar Anna in Research Group for 
Peptide Chemistry, Budapest, Hungary.  
 
 Receptor binding assays 
Radioligand binding assays are extremely powerful tools for studying 
receptors.  They allow an analysis of the interactions of related drugs with the 
receptors, studies of second messenger systems, and characterization of 
changes in receptor number and physiological function.  These assays were 
widely used by investigators in a variety of disciplines, including 
pharmacology, biochemistry, and cell biology.  
 
 [35S]GTPS binding assays 
[35S]GTPγS binding assays represent a functional test determinig agonist-
induced and receptor-mediated G-protein activation which is based on the 
increase in guanine nucleotide exchange at G-proteins upon agonist 
stimulation.  
 
 Isolated tissue bioassay 
The longitudinal muscle of the guinea pig ileum and the smooth muscle of the 
mouse and rat vas deferens were used for in vitro pharmacological 
characterization (efficacy, potency and selectivity) of the NOP receptor 
ligand, Ac-RYYRIR-ol. The mouse vas deferens, the rat vas deferens and the 
guinea pig ileum was prepared according to Bigoni et al., (1999).  
 
 Calcium-ion mobilization experiments  
Calcium mobilization assays were performed in a fluorometric imaging plate 
reader FlexStation II using the CHO cells expressing the recombinant human 
NOP receptor and the chimeric protein Gqi5. Maximum change in 
fluorescence, expressed as percent over the baseline fluorescence, was used to 
determine agonist response. 
 
 Internalization of the GFP tagged  hNOP receptor 
Ac-RYYRIR-ol regulated internalization of the NOP receptors were studied 
using HEK293 cells expressing the hNOP-GFP receptors. Olympus Cell-R 
fluorescence microscope was used with GFP filter set combination and 20 x 
objectives.  
 
 
 
 
 
 
 
 
 
 
SUMMARY OF THE RESULTS 
 
IDENTIFICATION OF THE NOVEL NATURALLY OCCURRING 
OPIOID PEPTIDES 
Our analysis of up to 55 different PENK and 39 PDYN sequences available in 
major protein databases showed that the pentapeptide and octapeptide units 
are variable among the different species studied. Among the novel peptides 
Ile-enkephalin (Tyr-Gly-Gly-Phe-Ile) was primarily observed in the African 
clawed frog (Xenopus laevis) PDYNs, while the structure of Phe-enkephalin 
(Tyr-Gly-Gly-Phe-Phe) was predicted by analyzing brain cDNA sequences 
encoding a prodynorphin of the African lungfish (Protopterus annectens).  
Four of the orthologous Met-enkephalin octapeptide sequences have been 
identified by bioinformatic means which were; YGGFMRGY (three frog 
species, platypus), YGGFMRSV (chicken, one fish species), YGGFMNGF 
(shark) and YGGFMRSL (mouse, two lungfish species). All the novel 
sequences were chemically synthesized and studied and compared to those of 
the well known Met-enkephalin-Arg6-Gly7-Leu8 and the pentapeptide Met-
enkephalin in receptor binding and G-protein activation assays performed on 
rat brain membranes. 
Our experimental findings revealed that newly recognized PDYN and PENK 
derived opioid sequences have good/moderate affinity towards opioid 
receptors.  Among pentapeptide enkephalin structures tested, Ile-enkephalin 
and Phe-enkephalins were found to be less effective than mammalian 
Met-enkephalin which exhibited the highest affinities in receptor binding 
assays and produced the most efficacious G-protein stimulation in brain 
membranes.  Of the four octapeptide structures studied, the ‘chicken type’ 
peptide variant (YGGFMRSV) exhibited the highest affinities in receptor 
binding assays.  These novel endogenously occurring sequences represent 
further examples of the natural diversity observed within the opioid peptide 
family. Importantly, these new endogenous peptides represent further 
illustration of the chemical biodiversity observed within the opioid peptide 
family. 
 
IN-VITRO PHARMACOLOGICAL CHARACTERIZATION OF A 
NOVEL, NOP SELECTIVE HEXAPEPTIDE, Ac-RYYRIR-ol 
The pharmacological profile of the novel hexapeptide Ac-RYYRIR-ol was 
investigated using various in vitro assays including receptor binding and G 
protein activation in rat brain membranes, mouse and rat vas deferens, guinea 
pig ileum, mouse colon and Ca2+ ion mobilization assay in chinese hamster 
ovary (CHO) cells co-expressing the human recombinant NOP receptor and 
the C-terminally modified Gαqi5 protein. Ac-RYYRIR-ol displaced [3H]Ac-
RYYRIK-ol with high affinity and stimulated [35S]GTPγS binding but 
showing lower maximal effects than N/OFQ.  In antagonist type experiments 
Ac-RYYRIR-ol inhibited the stimulatory effects induced by N/OFQ. 
Meanwhile in mouse colon Ac-RYYRIR-ol produced concentration 
dependent contractile effects with similar potency and maximal effects as 
N/OFQ and finally, in the Ca2+ ion mobilization assay Ac-RYYRIR-ol 
displayed lower potency.  NOP receptor selective hexapeptide Ac-RYYRIR-
ol had fine selectivity, high potency, furthermore agonist and antagonist 
effects toward the NOP receptors which is likely due to its partial agonist 
pharmacological activity. 
 
SELECTIVE AND HIGH AFFINITY LABELING OF THE NOP 
RECEPTORS WITH THE [3H]Ac-RYYRIK-ol 
Novel radiolabeled hexapeptide analogue [3H]Ac-RYYRIK-ol, selective for 
the NOP receptor has been described. Heterologous competition assays with 
various nociceptin analogues and some opioid compounds revealed that 
[3H]Ac-RYYRIK-ol specific binding was effectively inhibited by NOP 
receptor-selective ligands, whereas opioids displayed moderate to negligible 
affinities.  The results revealed that the new tritiated peptide analogue 
[3H]Ac-RYYRIK-ol recognized and labeled NOP receptors specifically in 
rat brain membrane preparations and in cellular system expressing the 
recombinant human NOP receptors. 
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